COMPASS Pathways plc (NASDAQ:CMPS) Short Interest Update

COMPASS Pathways plc (NASDAQ:CMPS) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 4,240,000 shares, an increase of 17.5% from the May 31st total of 3,610,000 shares. Based on an average daily trading volume, of 497,900 shares, the days-to-cover ratio is presently 8.5 days.

COMPASS Pathways Stock Up 0.8 %

COMPASS Pathways stock opened at $6.04 on Friday. The firm has a market cap of $413.02 million, a price-to-earnings ratio of -2.55 and a beta of 2.32. COMPASS Pathways has a 52 week low of $5.01 and a 52 week high of $12.75. The business’s 50-day moving average price is $7.46 and its 200 day moving average price is $8.87. The company has a quick ratio of 15.23, a current ratio of 15.23 and a debt-to-equity ratio of 0.12.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.03). As a group, sell-side analysts anticipate that COMPASS Pathways will post -2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a research note on Monday, May 13th. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, June 21st. Finally, Morgan Stanley assumed coverage on COMPASS Pathways in a research note on Monday, April 1st. They issued an “overweight” rating and a $30.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $47.40.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, major shareholder George Jay Goldsmith sold 23,881 shares of the stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total value of $203,704.93. Following the completion of the sale, the insider now directly owns 3,986,523 shares in the company, valued at $34,005,041.19. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders sold 59,252 shares of company stock worth $514,183. 4.25% of the stock is owned by insiders.

Institutional Trading of COMPASS Pathways

Several hedge funds and other institutional investors have recently bought and sold shares of CMPS. Armistice Capital LLC acquired a new stake in COMPASS Pathways during the third quarter worth about $2,960,000. Laurion Capital Management LP grew its holdings in COMPASS Pathways by 169.7% in the third quarter. Laurion Capital Management LP now owns 510,907 shares of the company’s stock valued at $3,781,000 after purchasing an additional 321,500 shares during the period. RA Capital Management L.P. acquired a new stake in COMPASS Pathways in the third quarter valued at approximately $9,516,000. TAP Consulting LLC grew its holdings in COMPASS Pathways by 14.7% in the third quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock valued at $95,000 after purchasing an additional 1,645 shares during the period. Finally, ARK Investment Management LLC grew its holdings in COMPASS Pathways by 7.6% in the fourth quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock valued at $22,915,000 after purchasing an additional 186,040 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.